Abiologics

Abiologics is a private, pre-clinical stage biotech founded in 2016 and based in San Diego, CA. The company's core innovation is its integrated platform combining generative AI for de novo design with high-throughput chemical synthesis to produce biologics from non-natural building blocks, like D-amino acids. This approach aims to create 'stealth' therapeutics with properties like immune evasion, protease resistance, and deep tissue penetration. As a Flagship Pioneering company, Abiologics is positioned to pioneer a new modality but faces significant technical and commercial risks inherent to novel platform development.

Integrated platform combining generative AI for de novo design of proteins using non-natural building blocks (e.g., D-amino acids) with high-throughput chemical protein synthesis to create 'Synteins™'—supranatural, programmable biologics with properties like immune evasion and protease resistance.

Abiologics competes with established protein engineering firms and big pharma biologics pipelines, as well as other next-generation modalities like RNA therapies and gene editing. Its unique angle is the full chemical synthesis of AI-designed, non-natural polymers, a niche with few direct competitors but unproven clinical viability.